Continue with Google Create account Don't have an account
Storage after reconstitution Mixing your semaglutide correctly is only valuable if you store it properly afterward
PubMed Randomized trialTirzepatide evidence2025 Tirzepatide for Obesity Treatment and Diabetes Prevention Supports newer discussion of obesity treatment and diabetes-prevention outcomes
Trial populations were predominantly conducted in North American settings with specific demographic characteristics that may limit generalisability
Next-generation agents include CagriSema (semaglutide + cagrilintide, NDA filed December 2025, showing 22.7% weight loss), retatrutide (triple GIP/GLP-1/glucagon agonist, 28.7% weight loss in Phase 3), and orforglipron (oral non-peptide GLP-1, submitted to FDA)
High DPP-4 concentrations in adolescents are associated with low intact GLP-1